Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) EV-to-Revenue : 6.99 (As of Jun. 03, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Biocytogen Pharmaceuticals (Beijing) Co's enterprise value is HK$7,347 Mil. Biocytogen Pharmaceuticals (Beijing) Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was HK$1,050 Mil. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue for today is 6.99.

The historical rank and industry rank for Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue or its related term are showing as below:

HKSE:02315' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.07 Med: 6.31 Max: 23.43
Current: 7.02

During the past 5 years, the highest EV-to-Revenue of Biocytogen Pharmaceuticals (Beijing) Co was 23.43. The lowest was 3.07. And the median was 6.31.

HKSE:02315's EV-to-Revenue is ranked better than
51.65% of 997 companies
in the Biotechnology industry
Industry Median: 7.39 vs HKSE:02315: 7.02

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-03), Biocytogen Pharmaceuticals (Beijing) Co's stock price is HK$17.98. Biocytogen Pharmaceuticals (Beijing) Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 was HK$2.64. Therefore, Biocytogen Pharmaceuticals (Beijing) Co's PS Ratio for today is 6.81.

Biocytogen Pharmaceuticals (Beijing) Co EV-to-Revenue Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co EV-to-Revenue Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

EV-to-Revenue

16.82

6.28

3.39

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
EV-to-Revenue	Get a 7-Day Free Trial				16.82	-	6.28	-	3.39

Competitive Comparison of Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue

For the Biotechnology subindustry, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue falls into.

Save Embed

;

Save Embed

;

Biocytogen Pharmaceuticals (Beijing) Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue	=	Enterprise Value (Today)	/	Revenue (TTM)
	=	7346.734	/	1050.445
	=	6.99

Biocytogen Pharmaceuticals (Beijing) Co's current Enterprise Value is HK$7,347 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Biocytogen Pharmaceuticals (Beijing) Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2024 was HK$1,050 Mil.

Biocytogen Pharmaceuticals (Beijing) Co (HKSE:02315) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Biocytogen Pharmaceuticals (Beijing) Co's PS Ratiofor today is calculated as:

PS Ratio	=	Share Price (Today)	/	Revenue per Share (TTM)
	=	17.98	/	2.64
	=	6.81

Biocytogen Pharmaceuticals (Beijing) Co's share price for today is HK$17.98.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2024 was HK$2.64.

Biocytogen Pharmaceuticals (Beijing) Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (HKSE:02315) » Definitions » EV-to-Revenue

Comparable Companies

Traded in Other Exchanges

I54:Germany

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Executives

Shen Yuelei
Ni Jian
Zhao Shang Yin Xing Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong You Xian Gong Si	2201 Interest of corporation controlled by you
Zhao Yin Guo Ji Jin Rong Kong Gu You Xian Gong Si	2201 Interest of corporation controlled by you
Cmbi Private Equity Series Spc	2201 Interest of corporation controlled by you
Cmb International Private Investment Limited	2201 Interest of corporation controlled by you
Cmb International Investment Management Limited	2201 Interest of corporation controlled by you
Astral Eminent Limited	2101 Beneficial owner
Wei Ke Xiang Gang Jing Mao You Xian Gong Si	2101 Beneficial owner
Bioveda China Fund Ii Rmb, Limited	2101 Beneficial owner
Bvcf Realization Fund Gp, Ltd.	2201 Interest of corporation controlled by you
Bvcf Realization Fund, L.p.	2201 Interest of corporation controlled by you
Innoveda Medtech, Ltd.	2201 Interest of corporation controlled by you
Yang Zhi	2201 Interest of corporation controlled by you

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines